Results 21 to 30 of about 16,928 (247)
KSHV LANA—The Master Regulator of KSHV Latency [PDF]
Viruses, 2014 Kaposi’s sarcoma associated herpesvirus (KSHV), like other human herpes viruses, establishes a biphasic life cycle referred to as dormant or latent, and productive or lytic phases. The latent phase is characterized by the persistence of viral episomes in a highly ordered chromatin structure and with the expression of a limited number of viral genes ...
Timsy Uppal +4 more
openaire +5 more sources
Viruses, 2021 Kaposi sarcoma-associated herpesvirus (KSHV) is the causative agent of multiple cancers in immunocompromised patients including two lymphoproliferative disorders associated with KSHV infection of B lymphocytes.
Nancy Palmerin +5 more
doaj +1 more source
Cell Death and Disease, 2021 Nucleocytoplasmic transport of signaling modulators is essential for regulating cellular responses to extracellular stimulation and stress, as well as pathogen infection. Exportin 1 (XPO1), also known as chromosomal maintenance 1 (CRM1), mediates nuclear
W. Meng, Shou-Jiang Gao
semanticscholar +1 more source
Chromatinization of the KSHV Genome During the KSHV Life Cycle [PDF]
Cancers, 2015 Kaposi’s sarcoma-associated herpesvirus (KSHV) belongs to the gamma herpesvirus family and is the causative agent of various lymphoproliferative diseases in humans. KSHV, like other herpesviruses, establishes life-long latent infection with the expression of a limited number of viral genes.
Timsy Uppal +3 more
openaire +3 more sources
Cell Host & Microbe, 2013 In this issue of Cell Host & Microbe, Chang and Ganem (2013) report that Kaposi's sarcoma-associated herpesvirus infection of lymphatic endothelial cells (LECs), but not blood endothelial cells (BECs), activates mTORC1 signaling and sensitizes LECs to rapamycin-induced killing.
Chris Boshoff, Ohad Yogev
openaire +3 more sources
Viruses, 2014 Twenty years ago, Kaposi’s sarcoma (KS) was the oncologic counterpart to Winston Churchill’s Russia: a riddle, wrapped in a mystery, inside an enigma. First described by Moritz Kaposi in 1872, who reported it to be an aggressive skin tumor, KS became known over the next century as a slow-growing tumor of elderly men—in fact, most KS patients were ...
Chang, Y, Moore, P
openaire +3 more sources
Viruses, 2020 Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan Africa.
Yasaman Mortazavi +5 more
doaj +1 more source
Investigation of CDH1 germline mutations in Turkish patients with Kaposi’s sarcoma
Türk Biyokimya Dergisi, 2022 Kaposi’s sarcoma (KS) develops from the lining cells of blood or lymphatic vessels and may appear as red, purple, brown, or black lesions. E-cadherin, CDH1, is a cell adhesion molecule located on the surface of epithelial cells.
Celik Betul, Tuncer Seref Bugra
doaj +1 more source
KSHV: forgotten but not gone [PDF]
Blood, 2011 Thirty years ago, Kaposi sarcoma (KS) arose as a prominent manifestation of the AIDS epidemic. Seventeen years ago we discovered the virus that causes KS,1 Kaposi sarcoma–associated herpesvirus (KSHV), and within a year KSHV had been also shown to be the likely cause of AIDS-associated primary effusion lymphoma (PEL)2 and most cases of multicentric ...
Moore, Patrick S., Chang, Yuan
openaire +3 more sources
SUMO and KSHV Replication [PDF]
Cancers, 2014 Small Ubiquitin-related MOdifier (SUMO) modification was initially identified as a reversible post-translational modification that affects the regulation of diverse cellular processes, including signal transduction, protein trafficking, chromosome segregation, and DNA repair.
Pei Ching Chang, Hsing Jien Kung
openaire +3 more sources